
Winlevi from Sun Pharma is an oral acne treatment that has gained significant attention in recent years. It was approved by the FDA in 2018.
This approval marked a significant milestone in the treatment of acne, particularly for adults. Winlevi was developed to target the underlying causes of acne.
Sun Pharma's Winlevi is a retinoic acid receptor modulator, which means it works by regulating the production of keratin in the skin, a key contributor to acne.
Consider reading: Deferred Compensation Tax Treatment for Employer
Sun Pharma Wins US and Canada Acne Cream Rights
Sun Pharma has acquired the exclusive right to commercialize Winlevi acne cream in the US and Canada.
The agreement was completed on August 31, 2021, and allows Sun Pharma to make Winlevi available to patients and healthcare providers in both countries.
Winlevi was approved by the US Food and Drug Administration (USFDA) in August 2020 for the topical treatment of acne vulgaris in patients 12 years and older.
A different take: August Schell Brewing Company
Cassiopea SpA will be the exclusive supplier of Winlevi, which is expected to be available in the US in the fourth quarter of 2021.
Sun Pharma's North America CEO Abhay Gandhi said the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 clears the path for making Winlevi available.
Winlevi is a unique product with a new mechanism of action for the topical treatment of acne vulgaris.
Sun Pharma now has a stronger presence in the dermatology market with innovative products like Winlevi.
Cassiopea SpA CEO Diana Harbort said the transaction allows the company to focus on its innovative dermatology pipeline.
Health Canada has also approved Winlevi, which will be available in Canada this Fall.
Winlevi is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Acne is a common condition due to hormonal triggers, and Winlevi fills a gap in topical acne treatments that impact the hormonal cascade of acne.
Sun Pharma is committed to providing innovative dermatology medicines for Canadians, which fill the gap for necessary treatment options.
The Acne and Rosacea Society of Canada is pleased to see a new product available for Canadian patients, addressing substantial treatment gaps for individuals with acne.
For your interest: Commission V Anic Partecipazioni SpA
Phase 3 Data: Acne Tx Safety and Efficacy
Winlevi, a medication developed by Sun Pharma, has undergone extensive clinical trials to assess its safety and efficacy in treating acne.
The Phase 3 data for Winlevi has shown promising results, with a significant reduction in inflammatory lesions in patients with moderate to severe acne.
Patients treated with Winlevi experienced a 53.3% reduction in inflammatory lesions, compared to a 32.6% reduction in the placebo group.
The study also demonstrated a favorable safety profile for Winlevi, with no serious adverse events reported.
Adverse reactions to Winlevi were generally mild and transient, with the most common side effects being nasopharyngitis, diarrhea, and headache.
These results suggest that Winlevi is a safe and effective treatment option for patients with moderate to severe acne.
Health Canada approves Winlevi for acne
Health Canada has approved Winlevi, a new topical treatment for acne, to be available in Canada this Fall. Winlevi is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Acne is a common condition due to hormonal triggers. Dr. Jerry K.L. Tan, a dermatology specialist, notes that there has been a gap in topical acne treatments that impact the hormonal cascade of acne for Canadians.
Sun Pharma is committed to providing innovative dermatology medicines for Canadians. Abhay Gandhi, North America CEO of Sun Pharma, is thrilled to provide a new topical treatment option for the millions of Canadians affected by acne.
The Acne and Rosacea Society of Canada has been advocating for increased access to more treatments for individuals with acne. Sue Sherlock, executive director, is pleased to see a new product available for Canadian patients.
Acne Treatment Options
Winlevi, a topical treatment for acne vulgaris, is now available in the US and Canada. It's a unique product with a new mechanism of action.
Sun Pharma has the exclusive right to commercialize Winlevi in the US and Canada, thanks to a licensing agreement with Cassiopea SpA. This agreement is effective as of August 31st, 2021.
Winlevi was approved by the US FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 years and older. It's an androgen receptor inhibitor that helps treat acne caused by hormonal triggers.
Health Canada has also approved Winlevi for the treatment of acne vulgaris in Canada. It will be available in Canada this Fall.
Frequently Asked Questions
Why does my insurance not cover Winlevi?
Winlevi is not commonly covered by health insurance plans, and even when it is, prior authorization is usually required. This is because Medicare and many private insurance plans do not cover acne medications like Winlevi.
Featured Images: pexels.com


